Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06251024
Registration number
NCT06251024
Ethics application status
Date submitted
1/02/2024
Date registered
9/02/2024
Date last updated
5/06/2024
Titles & IDs
Public title
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
Query!
Scientific title
A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine Candidate in Adult Participants 60 Years and Older
Query!
Secondary ID [1]
0
0
U1111-1271-1514
Query!
Secondary ID [2]
0
0
VAE00017
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infection
0
0
Query!
Healthy Volunteers
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - RSV vaccine candidate
Other interventions - Placebo
Experimental: Group 1: RSV vaccine candidate - Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the RSV vaccine candidate.
Placebo Comparator: Group 2: placebo - Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the placebo.
Other interventions: RSV vaccine candidate
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Other interventions: Placebo
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Presence of the first episode of RSV-LRTD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Assessment method [1]
0
0
Number of participants experiencing RSV-LRTD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Timepoint [1]
0
0
= 14 days after vaccination
Query!
Secondary outcome [1]
0
0
Presence of the first episode of RSV-ARD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Assessment method [1]
0
0
Number of participants experiencing RSV-ARD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Timepoint [1]
0
0
= 14 days after vaccination
Query!
Secondary outcome [2]
0
0
Presence of the first episode of RSV MAARD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Assessment method [2]
0
0
Number of participants experiencing RSV-MAARD (RSV A and/or RSV B) = 14 days after vaccination
Query!
Timepoint [2]
0
0
= 14 days after vaccination
Query!
Secondary outcome [3]
0
0
Presence of the first episode of RSV LRTD (RSV A) occurring = 14 days after vaccination)
Query!
Assessment method [3]
0
0
Number of participants experiencing RSV-LRTD (RSV A) = 14 days after vaccination
Query!
Timepoint [3]
0
0
= 14 days after vaccination
Query!
Secondary outcome [4]
0
0
Presence of the first episode of RSV LRTD (RSV B) occurring = 14 days after vaccination
Query!
Assessment method [4]
0
0
Number of participants experiencing RSV-LRTD (RSV B) = 14 days after vaccination
Query!
Timepoint [4]
0
0
= 14 days after vaccination
Query!
Secondary outcome [5]
0
0
Presence of the first episode of RSV-LRTD (RSV A and/or RSV B and by each one) by age group
Query!
Assessment method [5]
0
0
Number of participants experiencing RSV-LRTD (RSV A and/or B and by each one) by age group
Query!
Timepoint [5]
0
0
= 14 days after vaccination
Query!
Secondary outcome [6]
0
0
Presence of the first episode of RSV LRTD (RSV A and/or RSV B and by each one) by baseline comorbidities
Query!
Assessment method [6]
0
0
Number of participants experiencing RSV-LRTD (RSV A and/or B and by each one) by baseline comorbidities
Query!
Timepoint [6]
0
0
= 14 days after vaccination
Query!
Secondary outcome [7]
0
0
Presence of the first episode of RSV LRTD (RSV A and/or RSV B and by each one) by baseline frailty status
Query!
Assessment method [7]
0
0
Number of participants experiencing RSV-LRTD (RSV A and/or B and by each one) by baseline frailty status
Query!
Timepoint [7]
0
0
= 14 days after vaccination
Query!
Secondary outcome [8]
0
0
Presence of hospitalization due to RSV-ARD and/or RSV-LRTD
Query!
Assessment method [8]
0
0
Number of participants hospitalized due to RSV-ARD and/or RSV-LRTD
Query!
Timepoint [8]
0
0
= 14 days after vaccination
Query!
Secondary outcome [9]
0
0
Duration (number of days) of RSV LRTD episodes (RSV A and/or RSV B)
Query!
Assessment method [9]
0
0
Duration (number of days) of RSV LRTD episodes (RSV A and/or RSV B)
Query!
Timepoint [9]
0
0
= 14 days after vaccination
Query!
Secondary outcome [10]
0
0
Duration (number of days) of RSV ARD episodes (RSV A and/or RSV B)
Query!
Assessment method [10]
0
0
Duration (number of days) of RSV ARD episodes (RSV A and/or RSV B)
Query!
Timepoint [10]
0
0
= 14 days after vaccination
Query!
Secondary outcome [11]
0
0
Presence of the first episode of severe RSV LRTD (RSV A and/or RSV B and by each one) occurring = 14 days after vaccination
Query!
Assessment method [11]
0
0
Number of participants experiencing severe RSV-LRTD (RSV A and/or B and by each one)
Query!
Timepoint [11]
0
0
= 14 days after vaccination
Query!
Secondary outcome [12]
0
0
RSV A serum neutralizing antibodies (nAb) titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Assessment method [12]
0
0
RSV A serum neutralizing antibodies (nAb) titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Timepoint [12]
0
0
Day 1 and Day 29
Query!
Secondary outcome [13]
0
0
RSV B serum nAb titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Assessment method [13]
0
0
RSV B serum nAb titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Timepoint [13]
0
0
Day 1 and Day 29
Query!
Secondary outcome [14]
0
0
Serum anti-F immunoglobulin G (IgG) antibody (Ab) titers at pre-vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Assessment method [14]
0
0
Serum anti-F immunoglobulin G (IgG) antibody (Ab) titers at pre-vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset
Query!
Timepoint [14]
0
0
Day 1 and Day 29
Query!
Secondary outcome [15]
0
0
RSV A serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Assessment method [15]
0
0
RSV A serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Timepoint [15]
0
0
Month 6
Query!
Secondary outcome [16]
0
0
RSV B serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Assessment method [16]
0
0
RSV B serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Timepoint [16]
0
0
Month 6
Query!
Secondary outcome [17]
0
0
Serum anti-F IgG Ab titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Assessment method [17]
0
0
Serum anti-F IgG Ab titers at 6 months post-vaccination in the Immunogenicity Subset
Query!
Timepoint [17]
0
0
Month 6
Query!
Secondary outcome [18]
0
0
Presence of solicited injection site or systemic reactions
Query!
Assessment method [18]
0
0
Number of participants reporting:
injection site reactions: pain, erythema and swelling
systemic reactions: fever, headache, fatigue, myalgia, arthralgia and chills
Query!
Timepoint [18]
0
0
Within 7 days after primary vaccination
Query!
Secondary outcome [19]
0
0
Presence of unsolicited immediate systemic adverse events (AEs)
Query!
Assessment method [19]
0
0
Number of participants experiencing an unsolicited immediate systemic adverse event
Query!
Timepoint [19]
0
0
Within 30 minutes after primary vaccination
Query!
Secondary outcome [20]
0
0
Presence of unsolicited AEs
Query!
Assessment method [20]
0
0
Number of participants experiencing unsolicited AEs
Query!
Timepoint [20]
0
0
Within 28 days after primary vaccination
Query!
Secondary outcome [21]
0
0
Presence of serious adverse events (SAEs)
Query!
Assessment method [21]
0
0
Number of participants experiencing SAEs
Query!
Timepoint [21]
0
0
Throughout study (approximately 6 months)
Query!
Secondary outcome [22]
0
0
Presence of medically attended adverse events (MAAEs)
Query!
Assessment method [22]
0
0
Number of participants experiencing MAAEs
Query!
Timepoint [22]
0
0
Throughout study (approximately 6 months)
Query!
Secondary outcome [23]
0
0
Presence of adverse events of special interest (AESIs)
Query!
Assessment method [23]
0
0
Number of participants experiencing AESIs
Query!
Timepoint [23]
0
0
Throughout study (approximately 6 months)
Query!
Eligibility
Key inclusion criteria
- Aged 60 years or older on the day of inclusion
- A female participant is eligible to participate if she is not pregnant or
breastfeeding and:
• Is of non-childbearing potential. To be considered of non-childbearing potential, a
female must be postmenopausal for at least 1 year or surgically sterile.
- Participants with high-risk medical conditions who are determined by medical history,
physical examination (if required), and clinical judgment of the investigator to be
eligible for inclusion.
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following
criteria apply:
- Known or suspected congenital or acquired immunodeficiency; or receipt of
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
within the preceding 6 months; or long-term systemic corticosteroid therapy
(prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known systemic hypersensitivity to any of the study intervention components (eg,
polyethylene glycol, polysorbate); history of a life-threatening reaction to the study
interventions used in the study or to a product containing any of the same substances
;any allergic reaction (eg, anaphylaxis) after administration of an mRNA vaccine
- History of RSV-associated illness, diagnosed clinically, serologically, or
microbiologically in the last 12 months
- Previous history of myocarditis, pericarditis, and/or myopericarditis
- Thrombocytopenia, contraindicating IM injection based on investigator's judgment
- Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion,
contraindicating IM injection
- Chronic illness that, in the opinion of the investigator, is at a stage where it might
interfere with study conduct or completion
- Alcohol, prescription drug, or substance abuse that, in the opinion of the
investigator, might interfere with the study conduct or completion
- Receipt of any vaccine in the 4 weeks preceding any study intervention administration
or planned receipt of any vaccine in the 4 weeks following any study intervention
administration
- Receipt of any mRNA vaccine in the 60 days preceding any study intervention
administration or planned receipt of any mRNA vaccine in the 60 days following any
study intervention administration
- Previous vaccination against RSV with a licensed or investigational vaccine or planned
receipt during study participation, of vaccination against RSV with a licensed or
investigational vaccine other than the study vaccine
- Receipt of immune globulins, blood, or blood-derived products in the past 3 months
- Participation at the time of study enrollment (or in the 4 weeks preceding the first
study intervention administration) or planned participation during the present study
period in another clinical study investigating a vaccine, drug, medical device, or
medical procedure Note: The above information is not intended to contain all
considerations relevant to a patient's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/04/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
18/02/2025
Query!
Actual
Query!
Sample size
Target
4500
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Investigational Site Number : 0360003 - Botany
Query!
Recruitment hospital [2]
0
0
Investigational Site Number : 0360004 - Sippy Downs
Query!
Recruitment hospital [3]
0
0
Investigational Site Number : 0360001 - Southport
Query!
Recruitment hospital [4]
0
0
Investigational Site Number : 0360002 - Camberwell
Query!
Recruitment hospital [5]
0
0
Investigational Site Number : 0360005 - Norwood
Query!
Recruitment postcode(s) [1]
0
0
2019 - Botany
Query!
Recruitment postcode(s) [2]
0
0
4556 - Sippy Downs
Query!
Recruitment postcode(s) [3]
0
0
4222 - Southport
Query!
Recruitment postcode(s) [4]
0
0
3124 - Camberwell
Query!
Recruitment postcode(s) [5]
0
0
5067 - Norwood
Query!
Recruitment outside Australia
Country [1]
0
0
Dominican Republic
Query!
State/province [1]
0
0
Santo Domingo
Query!
Country [2]
0
0
Honduras
Query!
State/province [2]
0
0
San Pedro Sula
Query!
Country [3]
0
0
Honduras
Query!
State/province [3]
0
0
Tegucugalpa
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi Pasteur, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate
for the prevention of lower respiratory tract disease (LRTD) due to RSV.
The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to
receive a single intra-muscular (IM) administration of either a pre-determined dose of the
RSV vaccine candidate or placebo.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06251024
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trial Transparency email recommended (Toll free for US & Canada)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
800-633-1610
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06251024
Download to PDF